De plus, ce chiffre est plus qu'hypothétique puisqu'il est peu probable que la cible soit totalement couverte ,
A Role of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in the Treatment of Type 2 Diabetes, vol.32, 2011. ,
, , 2016.
, Agence de la santé publique du Canada Réduire le risque d'apparition du diabète de type 2 et de ses complications, 2016.
, Assurance maladie Améliorer la qualité du système de santé et maîtriser les dépenses // Proposition pour l'année 2017, 2017.
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, vol.325 ,
L Mesurons-nous suffisamment le coût des hypoglycémies? ,
, , pp.3-2017, 2017.
, , vol.20, 1999.
, Bohringer Ingelheim Résumé des caractéristique produit : Jardiance
Diabète et stress oxydant, 2016. ,
, , vol.11, 2016.
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes ,
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise [Article] // Diabetes Care.-2010, vol.10 ,
Effect of a multifactorial Intervention on Mortality in Type 2 Diabetes ,
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease, Am Heart J, vol.166 ,
, , 1910.
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, / Diabetes Care.-2014.-Emerging technology and therapeutics, vol.37 ,
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes, vol.36, 2016. ,
, IGAS Evaluation de la prise en charge du diabète // Evaluation de la prise en charge du diabète, 2012.
Monographie de produit Invokana®, 2017. ,
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind ,
acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2 [Article] // Can Fam Physicians, 2016. ,
Empagliflozin monotherapy in japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled ,
, // advances in therapy.-2014.-Adis.-6, vol.31
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus, vol.13 ,
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus, Clinical Pharmacology & Therapeutics, vol.85 ,
Etude de la Saxagliptine sur la survenue d'événements cardiovasculaire chez des patients diabétiques de type 2 (étude SAVOR-TIMI 53): description de l'étude et des patients [Article] // Médecine des maladies métaboliques, vol.7, 2013. ,
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial, vol.56 ,
, vers une remise à plat des critères d'évaluation, 2017.
Metabolic syndrome and socioeconomic status in France : The French Nutrition and Health Survey, International Journal of Public Health, vol.58, 2006. ,
Discovery of Dapaglifozin: A potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes ,
, J. Med. Chem, vol.51, pp.1145-1149, 2008.
, 13 Décembre, 2016.
Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branchedchain amino acid supplements [Article] // Diabetes Care, vol.20 ,
Dapagliflozide versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin, vol.34, 2011. ,
DK Cardiovascular effects of sodium glucose Cotransporteur 2 inhibitors: the search for the how and why, 01 Juillet, 2016. ,
, OCDE Panorama de la santé 2015 // Panorama de la santé, 2015.
, , 2016.
, Oppert JM Activité physique et rpévention cardio-vasculaire, pp.2004-2051
Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events [Article] // Drug saf, Springer international publishing switzerland, vol.37 ,
Épidémiologie et physiopathologie des complications dégénératives du diabète sucré, vol.1, pp.29-42 ,
J Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes, vol.12, 2005. ,
, , p.7, 2016.
Analyse économique des soins des personnes traitées pour diabète (étude entred, vol.41, 2001. ,
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, Lancet Diabetes Endocrinol, vol.1, 2013. ,
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of iinsulin in obese inadequately controlled type 2 diabetes, 2014. ,
Sécurité cardiovasculaire des antidiabétique [Article] // Revue médicale suisse, vol.12, 2016. ,
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes Metal Res Rev, vol.26 ,
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulphonylurea ,
, American Diabetes association, vol.36, 2013.
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis [Article] // Cardiovascular diabetology, BioMed central, 2016. ,
Efficacy and safety of canagliflozin montherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise, vol.15, 2013. ,
Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35): prospective observational study ,
, , vol.321
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate gycaemic control with glimerpiride: a randomized, 24-week, double-blind, p.13, 2011. ,
, , vol.10, 2016.
, The ADVANCE Collaborative Group Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.358, 2008.
, AE Mécanisme des complications du diabète : perspectives "thérapeutiques, vol.64
,
Treatment maintenance duration of dual therapy with metformin and sitagliptine ine type 2 diabetes: The ODYSSEE observational study, der Heuvel LP et Assink K et Willemsen M et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter, vol.41, pp.544-547 ,
, , vol.1
Cellular and molecular mechanisms of metformin: an overview [Article] // clinical science, vol.122 ,
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metforim and sulphonylurea: a randomised trial [Article] // The international journal of clinical practice, vol.12, 2013. ,
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years, vol.16, 2014. ,
, Yanick Farmer Denise Avard La composante génétique du diabète de type 2: suivi des progrès scientifiques du projet DGDG, vol.1, 2008.
, , 2011.
Efficacy and safety outcomes of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis ,
Nouvelle définition golbale du syndrome métabolique : raisonnement et résultats, vol.50, 2005. ,
Empagliflozin, cardiovadcular outcomes, and mortality in type 2 diabetes, vol.373, 2015. ,